Fundraising Fox
Retension Pharmaceuticals
Mclean, US · Founded 2023 · Delaware corporation · 13 employees on LinkedIn · 1 known investors
Find your way into Retension Pharmaceuticals
Sign up to see every warm intro you have to Retension Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Retension Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular disease. The company's lead compound, RTN-001, is a tissue-targeted PDE5 inhibitor designed to treat resistant hypertension through a differentiated mechanism targeting the central pulmonary vasculature.
Founders & leadership
Board
MB
Michael BerendtBoard director
DO
Donald OldsBoard director
Investors · 1
Funding
SEC filings, press & company announcements$22.4M disclosed across 2 of 3 rounds · 2023–2025
- Undisclosed amountSeries AAug 2024Source ↗
▶$12.3MraisedMay 2025 · 98 investors · PharmaceuticalsRule 506(b)
▶$12.3MraisedMay 2025 · 98 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric KellerExecutive Officer, Director
- Michael BerendtDirector
- Donald OldsDirector
- Offering amount
- $20M
- Amount sold
- $12.3M
- Sales commissions
- $701.4K
- Placement agents
- Collage Venture Partners, LLC, Stonehaven, LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$10.1MraisedMay 2024 · 132 investors · PharmaceuticalsRule 506(b)
▶$10.1MraisedMay 2024 · 132 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Donald OldsDirector
- Michael BerendtDirector
- Eric KellerExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $10.1M
- Sales commissions
- $727.5K
- Placement agents
- Stonehaven, LLC, Collage Venture Partners, LLC
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Retension Pharmaceuticals went on to found or lead other companies.
Related companies · 5
Redica SystemsRedica offers an AI-enriched intelligence platform that unifies global regulatory, inspection, site, and post-market data to help companies manage risk and protect product quality. It serves quality, regulatory, and supply chain teams across industries including pharmaceutical, medtech, cosmetics, supplements, food, and financial services.
Reven PharmaceuticalsReven is a biotech company developing RJX technology to address treatment needs for patients with limited therapeutic options. The company has conducted over a decade of research, including FDA-approved clinical studies and is currently investigating the technology's applications across multiple treatment modalities.
NovartisNovartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions. Its medicines include treatments for HR+/HER2- early breast cancer and polymyalgia rheumatica.
AdarepharmasolutionsAdare Pharma Solutions is a CDMO (contract development and manufacturing organization) and pharma services provider serving the biopharma industry with manufacturing, research and development, and patient support capabilities.
FoxbusinessFOX Business Network is a financial news channel that delivers real-time business and market information across multiple platforms. The network serves investors and business audiences interested in news affecting both retail and institutional markets.
Companies working in the same space as Retension Pharmaceuticals.
In the news
Frequently asked questions
- What does Retension Pharmaceuticals do?
- Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular disease. The company's lead compound, RTN-001, is a tissue-targeted PDE5 inhibitor designed to treat resistant hypertension through a differentiated mechanism targeting the central pulmonary vasculature.
- Who are Retension Pharmaceuticals's investors?
- Retension Pharmaceuticals's investors include Green Park & Golf Ventures.
- How much funding has Retension Pharmaceuticals raised?
- Retension Pharmaceuticals has disclosed $22.4M raised across 2 of its 3 known rounds.
- Where is Retension Pharmaceuticals headquartered?
- Retension Pharmaceuticals is headquartered in Mclean, US.